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Abstract
Bladder cancer is one of themost commonandaggressive cancers and, regardless of the treatment, often recurs
and metastasizes. Thus, a better understanding of the mechanisms regulating urothelial tumorigenesis is critical
for the design and implementation of rational therapeutic strategies. We previously discovered that the IGF-IR
axis is critical for bladder cancer cell motility and invasion, suggesting a possible role in bladder cancer
progression. However, IGF-IR depletion in metastatic bladder cancer cells only partially inhibited anchorage-
independent growth. Significantly, metastatic bladder cancer cells have decreased IGF-IR levels but
overexpressed the insulin receptor isoform A (IR-A), suggesting that the latter may play a more prevalent role
than the IGF-IR in bladder tumor progression. The collagen receptor DDR1 cross-talks with both the IGF-IR and
IR in breast cancer, and previous data suggest a role of DDR1 in bladder cancer. Here, we show that DDR1 is
expressed in invasive and metastatic, but not in papillary, non-invasive bladder cancer cells. DDR1 is
phosphorylated upon stimulation with IGF-I, IGF-II, and insulin, co-precipitates with the IGF-IR, and the IR-A and
transient DDR1 depletion severely inhibits IGF-I-induced motility. We further demonstrate that DDR1 interacts
withPyk2andnon-musclemyosin IIA in ligands-dependent fashion, suggesting that itmay link the IGF-IRand IR-
A to the regulation of F-actin cytoskeleton dynamics. Similarly to the IGF-IR, DDR1 is upregulated in bladder
cancer tissues compared to healthy tissue controls. Thus, our findings provide the first characterization of the
molecular cross-talk between DDR1 and the IGF-I system and could lead to the identification of novel targets for
therapeutic intervention in bladder cancer. Moreover, the expression profiles of IGF-IR, IR-A, DDR1, and
downstream effectors could serve as a novel biomarker signature with diagnostic and prognostic significance.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Bladder cancer is one of the most prevalent cancers
in the USA [1]. The prognosis for low-grade tumors is
generally favorable, but ~15% of these patients will
develop muscle-invasive disease, which has only a
50% survival rate at five years [2,3]. Compared to other
cancers, bladder cancer has the highest cost/patient
0022-2836/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (2020) 6–7, 100022
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ratio due to disease prevalence and necessary long-
term monitoring [4]. Surprisingly, this malignancy is
considerably understudied and underfunded in spite of
the high mortality [5,6].
The discoidin domain receptors, DDR1 and DDR2,
are non-integrin collagen receptors under the aus-
pices of the large receptor tyrosine kinase (RTK)
family (RTKs) [7–9]. Both receptors bind triple-helical
collagen. DDR1 and DDR2 bind and are mainly
activated by fibrillar collagen type I but can also bind
collagens type II, III and V. Collagen type IV interacts
with DDR1 but not with DDR2, which is specifically
activated by non-fibrillar collagen type X [10,11].
Structurally, DDRs possess a modular architec-
ture characterized by an extracellular discoidin
domain (ECD) and a juxta-membrane region
[12,13]. DDR1 can be expressed as five isoforms
by alternative splicing (DDR1a-e) and are widely
distributed in normal epithelium. In contrast, DDR2
has no isoforms and is expressed primarily in
stromal cells [9].
Interestingly, collagen evokes activation of DDR1
via lateral dimer association and phosphorylation
between dimers [14]. In striking contrast with other
RTKs, they have slow activation kinetics with Tyr-
phosphorylation occurring after several h of ligand
engagement [14–16]. It has been recently shown
that DDR1 kinase activity is determined by its
molecular density, and autophosphorylation of the
receptor leads to aggregation into large clusters [17].
This discovery provides a plausible mechanism for
well know slow kinetics of the receptor.
DDRs play essential roles throughout embryonic
development [7–9]. DDR-modulated cellular func-
tions include cell migration, cell survival, prolifera-
tion, and differentiation, as well as remodeling of
extracellular matrices [7–9]. Aberrant receptor sig-
naling is associated with the progression of various
human diseases, including fibrosis, arthritis, and
cancer [7–9,18,19], where DDR1 may promote
resistance to therapy [20].
Importantly, DDR1, although lacking a canonical
nuclear localization signal, is present in the nucleus
of injured renal tubules and evokes collagen Type IV
transcription [21]. Notably, DDR1 nuclear transloca-
tion requires collagen-mediated receptor activation
and interaction with SEC61B, non-muscle myosin
IIA, and β-actin.
The type 1 IGF receptor (IGF-IR) is a hetero-
tetrameric transmembrane tyrosine kinase receptor
composed of two α and two β subunits linked by
disulfide bridges [22]. The IGF-IR binds with high
affinity to both insulin-like growth factors I and II
(IGF-I and IGF-II) and plays an essential role in the
regulation of mammalian growth [23–28], and cell
differentiation in several cellular models, including
hemopoietic and neuronal cells [29–31]. In cancer,
the expression levels of the receptor and its natural
ligands are often altered and affect tumor initiation,
progression, and resistance to therapy [32–36]. IGF-
II, and to a lesser extent, IGF-I, binds to a second
RTK, the isoform A of the insulin receptor (IR-A). The
IR-A is highly homologous to the IGF-IR [22,37,38]
and promotes mitogenic effects upon IGF-II or
insulin binding [38–40], an action that may be
important in several cancer models [22,41–43].
Moreover, the IR-A metabolically reprograms breast
cancer cells in response to co-stimulation of IGF-II
and insulin [11]. The second IR isoform (IR-B) is
critical for glucose metabolism of insulin-responsive
organs [22,38,41]. The IR-A is preferentially
expressed over the IR-B, and an autocrine prolifer-
ative loop between IGF-II and the IR-A exists in
malignant thyrocytes and breast cancer [22,43–48].
Recent work from our laboratories has established a
critical role of the IGF-IR in bladder cancer [49–51].
IGF-IR expression increases with tumor grade and
stimulates the ability of urothelial cancer cells to
migrate through and evade a 3D extracellular matrix
[49]. Importantly, the extracellular matrix actively
regulates IGF-IR, and IR-A [51] and a finely coordi-
nated cross talk between IGF-IR and the epidermal
growth factor receptor (EGFR) regulates the expres-
sion of matrix molecules such as proteoglycans [52].
Proteoglycan remodeling is emerging as a crucial step
in regulating cancer phenotype and aggressiveness
[53], vascular disease [54], neuro-inflammation [55],
cardiac fibrosis [56,57], and tissue homeostasis and
repair [58]. In cancer, the remodeling of multiplematrix
proteins has been associated with the regulation of
tumor neovascularization [59,60] and major biological
processes [61,62], including tissue stiffness [63] and
cardiac disease [64] For example, decorin, the most
studied member of the small leucine-rich family of
proteoglycans [65–68] binds with high affinity to both
IGF-IR and IGF-I and represses IGF-IR activity in
bladder cancer cells [50]. Decorin expression is
absent in bladder tumor tissues [50], suggesting that
its loss is permissive for tumor growth and may
modulate IGF-IR activity in urothelial carcinomas and
perhaps other tumor types where IGF-IR plays a role.
Further, decorin binds the IR-A and its associated
ligands IGF-II, insulin, and proinsulin, although with
different affinities [69]. Decorin does not affect ligand-
mediated IR-A phosphorylation, but it attenuates IGF-
II-inducedAkt activation, promotes IGF-II-evoked IR-A
downregulation and reduces IGF-II-mediated cell
growth [69]. Importantly, decorin does not affect insulin
or proinsulin-evoked biological responses down-
stream of the IR-A [69]. These discoveries support a
new mechanism whereby decorin loss contributes to
tumor formation in cancer systems addicted to an IGF-
II/IR-A tumorigenic autocrine loop.
A putative oncogenic role for DDR1 [70] and DDR2
[71] was recently suggested in bladder cancer, and
we demonstrated a functional interaction between
DDR1 and both the IGF-IR and IR in breast cancer
[11,72–76]. DDR1 potentiates the biological actions
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of insulin, IGF-I, and IGF-II. Conversely, DDR1 is
upregulated by IGF-I, IGF-II, and insulin through the
PI3K/AKT/miR-199a-5p signaling cascade [76].
These data suggest a more comprehensive role of
DDR1 as amodulator of cell responses to hormones,
growth factors, and signals from the extracellular
matrix. However, whether DDR1 may functionally
cross-talk with the IGF system and modulate IGF-
evoked biological responses in bladder cancer has
not been established.
Here we show that the IGF-IR is necessary but not
sufficient for anchorage-independent growth of
metastatic bladder cancer cells suggesting that the
IR, and specifically the IR-A, may play a more critical
role in bladder cancer progression. We further
demonstrate that DDR1 modulates IGF-IR and IR-
A-dependent bladder cancer cell motility by linking
the IGF-IR and IR-A to the regulation of F-actin
cytoskeleton dynamics. Untangling the intricacies of
receptor cross-talk between the IGF-I system and
DDR1 will significantly contribute to the identification
of novel targets and biomarkers for advanced
therapeutic intervention in bladder tumors.
Results
IGF-IR loss partially inhibits migration and
anchorage-independent growth
We previously demonstrated that activation of the
IGF-IR pathway promotes motility and invasion of
bladder cancer cells [49–51]. These results provided
the first evidence that the IGF-I system plays an
essential role in bladder cancer and may drive the
transition to the invasive phenotype. To determine
whether the IGF-IR may be critical for bladder cancer
formation, we stably depleted endogenous IGF-IR in
T24T urothelial cancer cells. T24T cells are trans-
forming isogenic derivatives of T24 cells and grow in
soft-agar, generate tumors, and form metastases in
nude mice [77–79]. We discovered that IGF-IR
depletion (Fig. 1A) only partially reduced cell
migration in 1% serum-condition (Fig. 1B) and
colony formation in anchorage-independent growth
(Fig. 1C). Representative images depict colony
formation from shScr control or shIGF-IR#4 T24T
cells (Fig. 1D).
As mentioned above, increasing evidence indicates
that the IR-A may be involved in the pathogenesis of
cancer [41,42]. Notably, the IR-A is the dominant IR
isoform present in several bladder cancer cells [83].
Thus, we evaluated the relative protein expression of
IGF-IR and IR in various bladder cancer cell lines with
diverse malignant behavior. Surprisingly, IGF-IR levels
were low in tumorigenic and metastatic T24T and
UMUC3 cells, which instead expressed high levels of
the IR (Fig. 1E), presumably ~70% is the IR-A isoform
[83]. T24cells,which are invasive but not tumorigenic in
vivo, express the IGF-IR and undetectable levels of the
IR, whereas 5637 cells are tumorigenic in vivo but do
not formmetastases, and express high levels of IGF-IR
and IR (Fig. 1E). However, in 5637 cells, the ratio IR-A
vs. IR-B is 50:50, as previously demonstrated [83].
These findings suggest that IGF-IR is important but not
sufficient for migration and anchorage-independent
growth.
Fig. 1. IGF-IR depletion in metastatic T24T cells only partially inhibits motility and anchorage-independent growth. (A)
IGF-IR depletion in T24T cells was obtained by stable transfection of the pRS/shIGF-IR plasmid or control and subsequent
selection in puromycin-containing media. (B) Migration of T24T cells was assessed in Boyden chambers as described
[49,80,81].*p b 0.05. (C) Anchorage-independent growth was measured by soft-agar assays. Colonies ≥150 μM were
counted [82]. Experiments are the average of three independent experiments ±SD. Bar~200 μm. *p b 0.05. (D)
Representative colonies generated from shScr or shIGF-IR#4 transfected T24T cells. (E) IGF-IR and IR expression levels
in various urothelial carcinoma-derived cells were assessed by immunoblot with anti-IGF-IR and anti-IR polyclonal
antibodies. β-Actin served as the loading control.
3
IGF-IR and IR-A differentially contribute to
urothelial cancer cell motility
To assess the contribution of the IGF-IR and IR-A
to the migratory ability of urothelial cancer cells, we
compared the migration of T24 and T24T cells after
stimulation with equimolar physiological concentra-
tions of IGF-I, IGF-II, and insulin [69,84]. While T24
cells preferentially responded to IGF-I and a lesser
extent to IGF-II and insulin (Fig. 2), IGF-II and insulin
evoked a stronger migratory response in T24T cells
compared to IGF-I (Fig. 2).
These findings suggest that in metastatic bladder
cancer cells, the IR-A, activated by both IGF-II and
insulin, may play a more prominent role than the IGF-
IR in modulating cancer cell motility.
DDR1 is expressed in bladder cancer cells and
interacts with the IGF-IR and IR
Proteomic studies have recently identified DDR1
as a novel substrate of the IR-A [72]. We recently
established that this receptor functionally modulates
IGF-IR and IR-A action in breast cancer [48,73–76],
suggesting that a functional cross-talk between
DDR1 and the IGF system may occur in bladder
cancer, where both IGF-IR [49–51] and DDR1 play
an important role [70]. To investigate whether DDR1
cross-talks with the IGF-I signaling axis, we first
assessed baseline expression levels of this RTK in
various bladder cancer cells. DDR1 was expressed
in invasive (T24 and 5367) and metastatic (T24T and
UMUC3), but not in papillary non-invasive (RT4)
cells (Fig. 3A). 5637 cells expressed both DDR1a
and DDR1b isoforms, whereas T24, T24T, and
UMUC3 cells mainly expressed DDR1a (Fig. 3A)
[7,9], with a slight amount of DDR1b in T24T. We
found that DDR1b was detectable only after over-
exposure of the film. Whether the bands detectable
around 60 kDa are soluble, partially processed
receptor forms [12], remain to be established
(Fig. 3A, arrow). To determine if DDR1 may
contribute to the IGF-I system to regulate cell
motility, we determined whether it might associate
with the IGF-IR and/or the IR. In 5637 cells, DDR1a
was not detectable in immunoprecipitates from
serum-s ta rved ce l l l ysa tes bu t d id co-
immunoprecipitate with the IGF-IR after 5 min of
IGF-I stimulation (Fig. 3B). In T24T cells, instead,
DDR1a was constitutively associated with the IR and
this association increased after insulin stimulation
(Fig. 3C).
Collectively, these findings suggest that DDR1a
interacts with the IGF-IR and IR in bladder cancer
cells. However, the kinetics of association between
DDR1a and the IGF-IR in invasive cells (e.g., 5637)
may differ from the interaction with the IR in
metastatic cells (e.g., T24T).
DDR1 is phosphorylated by IGF-I, IGF-II, and
insulin in bladder cancer cells and is required
for IGF-I-induced migration
Next, we tested whether DDR1 would be phos-
phorylated by IGF-I in 5637 or by IGF-II and insulin in
T24T cells. Notably, IGF-I, IGF-II, and insulin-
induced phosphorylation of DDR1 as early as
10 min and remains activated up to 30 min
(Fig. 4A, B). In agreement with our previous results
[76], this observation suggests very different kinetics
from collagen-dependent receptor activation, which
is very slow and requires several h of collagen
stimulation [7,15,16,85]. We then established wheth-
er DDR1 is necessary for IGF-IR-dependent motility
of 5637 cells. Specific RNAi-mediated depletion of
endogenous DDR1 (Fig. 4C) severely inhibited IGF-
I-induced migration of invasive 5637 cells as
compared to siRNA-control-transfected cells
(*p b 0.05, **p b 0.01) (Fig. 4D).
These results indicate that DDR1 is necessary for
IGF-I-induced motility, corroborating the notion that
cross-talk between DDR1 and IGF-I system is
biologically relevant in bladder cancer progression.
Stable depletion of DDR1 in UMUC-3 cells
inhibits anchorage-independent growth
To determine whether DDR1 is critical for
anchorage-independent growth, we used shRNA to
stably deplete it in invasive UMUC-3 cells, which
forms colonies in soft-agar assays [80,81]. We
isolated two pools of UMUC-3 cells showing
significant DDR1 depletion (~80–90%) (Fig. 5A).
Fig. 2. IR-A plays a critical role in modulating bladder
cancer cell motility. Analysis of IGF-I, IGF-II, or insulin-
inducedmigration of T24 or T24T cells. Migration of serum-
starved T24 or T24T cells after 18 h of stimulation with
ligand was assessed in Boyden chambers as described
[49,80,81]. Experiments are the average of three indepen-
dent experiments. *p b 0.05.
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Notably, DDR1-deficient cells produced very few
colonies in soft-agar (**p b 0.01, ***p b 0.001,
Fig. 5B, C).
These results imply a critical role for DDR1 in
regulating anchorage-independent growth of urothe-
lial cancer cells.
IGF-I and IGF-II regulate F-actin networks of
bladder cancer cells
Our work has established the role of the IGF-IR in
the motility of bladder cancer cells [49,50], and
additional experiments have demonstrated an
Fig. 3. DDR1 is expressed in bladder cancer cells and interacts with the IGF-IR and IR. (A) Immunoblotting of DDR1
using an anti-DDR1 polyclonal antibody towards its C-terminus.DDR1c was not detectable in these experimental
conditions (50 μg of lysate). (B) 2.5 mg of 5637 cell lysates were immunoprecipitated with anti-IGF-IR monoclonal
antibodies after 5 min stimulation with 10 nM of IGF-I. Total IGF-IR was detected using an anti-IGF-IR polyclonal antibody.
(C) 2 mg of T24T cell lysates were immunoprecipitated with anti-IR monoclonal antibodies after 5-min stimulation with
10 nM of IGF-II or insulin. Total IR was detected using an anti-IR polyclonal antibody.
Fig. 4. DDR1 is phosphorylated by IGF-I, IGF-II, and insulin in 5637 and T24T bladder cancer cells and is required for
IGF-I-induced migration of 5637 cells. (A) DDR1 phosphorylation after stimulation with 10 nM IGF-I (5637), (B) IGF-II, and
insulin (T24T) for 10 or 30 min was assessed by immunoblot using Phospho-DDR1 antibodies (Tyr792). Total DDR1
expression was determined using anti-DDR1 polyclonal antibodies. (C) DDR1 was depleted by siRNA and DDR1 levels
were assessed by immunoblot with anti-DDR1 polyclonal antibodies and normalized to β-actin. Densitometric analysis
was performed using ImageJ (National Institute of Health) and expressed as arbitrary units. (D) Migration of serum-starved
and DDR1-depleted 5637 cells after stimulation with IGF-I (10 nM) was assessed at 18 h as previously described.
*p b 0.05, **p b 0.01.
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interaction between DDR1 and myosin IIA, which
impact cell spreading and migration by regulating
adhesive contacts with collagen [86]. Based on
these observations, we hypothesize that a specific
interaction between DDR1 and the IGF-IR/IR would
regulate cell migration by controlling actomyosin and
focal adhesion dynamics. Thus, we assayed wheth-
er IGF-IR or IR-A activation would affect cytoskeletal
structures. Bladder cancer cells were stimulated in
serum-free media (SFM) with physiological concen-
trations of IGF-I or IGF-II (10 nM) and F-actin
dynamics visualized with Alexa Fluor® 594-
phalloidin. In unchallenged conditions, both 5637
and T24T showed intense cortical F-actin staining at
cell-cell contacts and in the organized network of the
cytoskeleton (Fig. 6A, SFM arrows). In contrast, the
F-actin cytoskeletal network was significantly dis-
rupted after 10 min of IGF-I or IGF-II stimulation
(Fig. 6A, IGF-I or IGF-II 10′), with progressive
disruption of F-actin cortical structures at cell-cell
contacts (Fig. 6A, IGF-I or IGF-II 30′).
Collectively, these results indicate that IGF-IR and
IR-A activation might regulate actomyosin turnover
and support our hypothesis that DDR1 may regulate
bladder cancer cell motility by linking the IGF-IR and
IR-A to the regulation of the F-actin network.
DDR1 associates with the IGF-IR or IR, Pyk2 and
non-muscle myosin IIA
To further define the molecular mechanisms by
which IGF-IR (or IR) activation may regulate the
actomyosin cytoskeleton, we performed co-
immunoprecipitation experiments assessing wheth-
er DDR1 and IGF-IR/IR could interact with Pyk2 or
myosin IIA, which regulates focal adhesions [51].
DDR1 and myosin IIA cooperate to regulate
collagen-dependent cell spreading and motility [86].
Serum-starved 5637 and T24T cells were stimulated
with IGF-I (5637 cells), IGF-II or insulin (T24T cells),
and lysates immunoprecipitated with anti-DDR1
antibodies. In both 5637 (Fig. 6B) and T24T cells
(Fig. 6C), DDR1 associated with Pyk2 and myosin
IIA and the interactions were increased after IGF-I
(Fig. 6B), IGF-II or insulin (Fig. 6C) stimulation. Pyk2
expression was significantly lower in T24T cells and,
therefore not detectable (Fig. 6C). We also detected
the IGF-IR (Fig. 6B) and IR (Fig. 6C) in DDR1 co-
immunoprecipitates, confirming our previous exper-
iments (Fig. 3) and the association between this
receptor and the IGF-IR (in 5637 cells) and the IR (in
T24T cells). These data indicate that DDR1may be a
part of a multi-protein complex including Pyk2,
myosin IIA, and the IGF-IR or IR. This complex
may be critical for bladder cancer cell motility by
regulating actin skeleton dynamics.
Analysis of DDR1 expression in a bladder
cancer tissue microarray
To investigate whether DDR1 may work in
conjunction with the IGF-IR as a diagnostic or
prognostic biomarker for bladder cancer, we per-
formed immunohistochemical analysis of DDR1
expression in an AccuMax™ bladder cancer tissue
microarray. This tissue array contained 43 cases of
urothelial carcinoma, 7 adenocarcinoma, 6 squa-
mous cell carcinoma, 4 metastatic carcinoma and 9
bladder tissue, triplicate cores per case. In contrast
to normal bladder mucosa (Fig. 7A), DDR1 was
highly expressed in both carcinoma in situ (Fig. 7B)
as well as in all the forms of bladder cancer studied
(Fig. 7C–H). Notably, bladder cancer cells
expressed DDR1 both at the cell surface and within
the cytoplasm. DDR1 positivity was noted in nests of
poorly differentiated urothelial carcinoma cells (ar-
rows, Fig. 7H).
These results suggest that DDR1, IGF-IR, and
possibly IR levels, may constitute a novel biosigna-
ture predictive of bladder cancer progression.
Discussion
Bladder cancer is among the most common solid
tumors in the United States, with an alarming 80,470
Fig. 5. DDR1 depletion inhibits anchorage-independent growth of UMUC-3 cells. (A) DDR1 depletion was achieved by
shRNA. Stably-depleted DDR1 UMUC-3 cells were analyzed for DDR1 expression by immunoblot with anti-DDR1
antibodies. DDR1 expression was quantified to β-actin by densitometric analysis using ImageJ. (B) (C) Anchorage-
independent growth was assessed by colony formation via soft-agar assays [80,81]. Colonies ≥150 μmwere counted [82].
Mean ± SD of three biological replicates; **p b 0.01, ***p b 0.001.
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new cases and 17,670 predicted deaths in 2019 [1];
however, a profound lack of knowledge on the
molecular mechanisms that govern tumor formation
and metastasis persists in the field.
Our laboratories demonstrated that activated IGF-
IR functions as a “scatter factor” and induces motility
and invasion without affecting cell proliferation [49].
IGF-IR-evoked Akt and MAPK pathways and IGF-I-
induced Akt- and MAPK-dependent phosphorylation
of paxillin, which relocated to focal adhesions, and
was necessary for promoting motility of bladder
cancer cells. These results are innovative, consid-
ering that the IGF-IR in most other cancers promotes
cell proliferation and survival [33]. Furthermore,
while IGF-IR action and regulation are well charac-
terized in cell survival [87], the mechanisms modu-
lating IGF-IR activity in motility and invasion are still
very poorly defined. Moreover, whether the IR may
crosstalk with the IGF-IR in bladder cancer progres-
sion and dissemination has not been previously
established.
In the present study, we show that: (A) Stable IGF-
IR depletion in metastatic bladder cancer cells only
partially inhibits motility and anchorage-independent
growth. (B) Tumorigenic and metastatic bladder
cancer cells express lower levels of IGF-IR but
overexpress the IR-A. (C) Expression of the collagen
receptor DDR1 enhances bladder cancer progres-
sion. (D) DDR1 is phosphorylated by IGF ligands
and interacts with IGF-IR and IR. (E) IGF-I and IGF-II
regulate F-actin dynamics and the formation of a
multi-protein complex, which includes IGF-IR/DDR1
or IR-A/DDR1, Pyk2, and non-muscle myosin IIA,
and (F) DDR1 expression is upregulated in human
bladder cancer tissues compared to healthy
controls.
The extracellular matrix regulates IGF signaling
in physiology and disease. In particular, the
Fig. 6. The IGF-system and DDR1 modulate F-actin networks. (A) 5637 and T24T cells were serum-starved for 18 h,
and then stimulated with 10 nM IGF-I or IGF-II for 10 or 30 min. F-actin was detected by staining with Alexa Fluor® 594-
phalloidin, followed by confocal analysis. Images are representative of 10 independent fields from three independent
experiments. An average of 100 cells/condition was examined. White arrows point to reorganization and remodeling of the
actin filaments and loss of cortical actin upon stimulation with the growth factors. Nuclei were stained with DAPI. Bar
~10 μm. (B) 5637 and (C) T24T cells were serum-starved for 18 h and stimulated for 5 min with 10 nM of IGF-I, IGF-II, or
insulin. Lysates were immunoprecipitated with anti-DDR1 polyclonal antibodies. Immunoblots were performed using
specific antibodies for Pyk2, myosin IIA heavy chain, IGF-IR or IR, and DDR1.
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smal l leuc ine r ich proteog lycan decor in
[53,58,66–68,88,89] modulates IGF-IR activity by
regulating IGF-IR phosphorylation and activation of
downstream effectors [90]. In non-transformed cells,
decorin mimics IGF-I, thereby functioning as an IGF-
IR agonist to regulate specific biological responses
[51]. Conversely, decorin counteracts IGF-IR action
in bladder cancer cells and negatively regulates IGF-
I-evoked physiological reactions [50]. As an addi-
tional layer of regulation, decorin binds the IR-A and
IR-A ligands, IGF-II, insulin, and proinsulin, with a
hierarchy of affinities [69], but preferentially sup-
presses IGF-II-dependent IR-A activation of down-
stream signaling [69]. Collectively, these results
suggest an exciting, functional dichotomy of decorin
towards the IGF-I system in non-transformed versus
cancer cells and the ligand-specific regulation of IR-
A [51]. Cancer cells often produce IGF-II, and an
autocrine loop involving IGF-II and the IR-A stimulates
thyroid cancer growth [44]. Additionally, DDR1 regu-
lates thyroid cancer cell differentiation via an IGF-2/IR-
A autocrine signaling loop [11]. Importantly, urothelial
bladder carcinomas produce IGF-II [91,92] suggesting
that decorin loss in the tumor microenvironment may
enhance IGF-II-evoked and DDR1-regulated IR-A for
bladder cancer progression.
To further elucidate the role of the IGF-IR in
regulating urothelial tumorigenesis, we initially test-
ed IGF-IR function in anchorage-independent
growth. Surprisingly, IGF-IR depletion only partially
reduced the ability of bladder cancer cells to grow in
a soft-agar assay. Thus, we hypothesize that the IR-
A, which is the IR isoform preferentially expressed in
metastatic bladder cancer [83], may work in con-
junction with the IGF-IR in driving bladder cancer
progression. Indeed, recent studies support the
concept that both IR isoforms are broadly over-
expressed in human tumors and that the IR-A/IR-B
ratio is skewed to favor the IR-A isoform [22]. Studies
have also demonstrated that IR isoforms act in strict
connection with the IGF-IR, often forming heterodi-
meric receptor complexes [22], which are activated
by multiple IGF ligands, usually produced by cancer
cells [22]. However, whether IGF-IR/IR-A hybrids are
present and activated in an autocrine or paracrine
manner in bladder cancer cells has not yet been
determined.
Based on our previous observations that the
collagen receptor DDR1 functionally interacts with
both the IGF-IR and IR in breast cancer [11,72–76]
and prior reports on the relevance of DDR1 [70] and
DDR2 [71] in bladder cancer, we determined
whether DDR1 may regulate IGF-IR/IR in bladder
cancer. Our results suggest that this RTK is critical in
regulating IGF ligand-evoked cell motility and
anchorage-independent growth by functionally inter-
acting with the IGF-IR and IR. DDR1 is expressed in
five different isoforms, three of which are full-length,
functional RTKs (DDR1a, DDR1b, and DDR1c),
while DDR1d and DDR1e are truncated or kinase-
Fig. 7. DDR1 expression in bladder cancer tissue microarrays. DDR1 expression was determined by immunohisto-
chemistry using a specific anti-DDR1 rabbit monoclonal antibody on a Biomax human bladder cancer tissue microarray.
Mu, mucosa. The arrows in panel H point to nests of poorly differentiated, urothelial carcinoma cells (brown) infiltrating the
negative stroma. Bar ~200 μm.
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inactive [12,13]. We discovered that DDR1a is the
isoform prominently expressed in the majority of
invasive and metastatic bladder cancer, while 5637
cells express a considerable amount of DDR1b as
well, albeit at lower levels. These data suggest that
DDR1a is likely the active isoform in bladder cancer
cells, but further studies are required to determine
whether multiple isoforms may also contribute to its
oncogenic function. We hypothesize that different
isoforms may have opposite effects by acting in a
dominant negative manner towards DDR1a, thus
negatively regulating IGF-evoked bladder cancer
cell motility. Recent data indicate that DDR1
translocates to the nucleus, where it regulates
collagen transcription [21]. Significantly, there is
strong evidence that both the IGF-IR and the IR
also translocate to the nucleus [93–99], but whether
DDR1 translocation may be mechanistically linked
with the IGF-IR or IR remains to be elucidated.
Efficient cancer cell migration depends on dynam-
ic interactions between F-actin, myosin II, microtu-
bules, and focal adhesions [100–102]. The ATPase
function of non-muscle myosin IIA (NMHC-IIA)
allows transient binding to the actin cytoskeleton,
which generates mechanical forces essential to
maintain cellular architecture or to initiate cell motility
[101–104]. Mouse embryos lacking Nmhc-IIA die at
an early stage of development, confirming the
fundamental role of myosin IIA in cellular function
[105]. Recent data have demonstrated an interaction
between DDR1 and myosin IIA, which impacts cell
spreading and migration by regulating adhesive
contacts with collagen [86]. We discovered that
IGF-I-induced paxillin-regulated focal adhesion dy-
namics of invasive bladder cancer cells [49].
Significantly, DDR1 and Pyk2 contribute to
collagen-dependent up-regulation of N-cadherin
and enhanced motility [106]. Based on these
observations, we hypothesize that a specific RTK
interaction between DDR1 and the IGF-IR/IR would
regulate cell migration by controlling actomyosin and
focal adhesion dynamics. We believe that the IGF-
IR/DDR1 and IR-A/DDR1 complexes recruit Pyk2
and non-muscle myosin IIA in a ligand-dependent
manner is an innovative and posits a novel,
functional link to the F-actin cytoskeleton as a
regulatory mechanism driving bladder cancer cell
motility.
Growth factor-dependent phosphorylation of myo-
sin IIA heavy chain plays an essential regulatory role
in mediating cell motility and chemotaxis of breast
cancer cells [107]. Specifically, myosin IIA phos-
phorylation at Ser1293 is a critical step in regulating
locomotion of mammary carcinoma cells [107].
However, we did not determine in this study whether
IGF ligands may promote myosin IIA phosphoryla-
tion, and further experiments are required to address
this issue. As non-muscle myosin IIA affects not only
motility, but also the adhesive ability of migrating
cells [101–104], we postulate that myosin IIA may
not regulate cell motility, but instead modulate IGF-
regulated cell adhesion, a critical step for metastatic
cells to colonize distant organs.
In conclusion, our data provide essential informa-
tion to understand better the molecular mechanisms
that regulate bladder cancer progression and offer
valuable insight for translational research. Once fully
characterized, the roles of the IGF-IR, IR, and DDR1
in bladder cancer could contribute to the identifica-
tion of novel targets for therapeutic intervention.
Furthermore, the IGFI-R, IR, and/or DDR1 may
prove useful as clinical biomarkers for detecting
bladder cancer.
Materials and methods
Cell lines
Urothelial carcinoma-derived human RT4, 5637,
T24, and UMUC-3 cells were obtained from the
ATCC. T24T cells (a kind gift from Dr. Dan
Theodorescu, University of Colorado Cancer Cen-
ter) are more aggressive isogenic derivatives of T24
cells that grow in soft-agar, [77–79]. RT4, 5637 and
T24 cells were maintained in RPMI medium supple-
mented with 10% fetal bovine serum (FBS). UMUC-3
cells were maintained in MEM with EARL medium
with 10% fetal bovine serum (FBS), while T24T cells
were maintained in DMEM/F12 medium supple-
mented with 10% FBS. Serum-free medium (SFM)
is DMEM supplemented with 0.1% bovine serum
albumin and 50 μg/ml of transferrin (Sigma-Aldrich).
Recombinant IGF-I was purchased from Calbiochem
(San Diego, CA). Recombinant bovine insulin was
from Sigma-Aldrich, while recombinant IGF-II was
from PreproTech.
Generation of IGF-IR- and DDR1-depleted blad-
der cancer cells
Transient DDR1 depletion in 5637 cells was
achieved by siRNA. DDR1-specific siRNA were
SMART pool oligos designed by Dharmacon. Cells
were transfected using the TransIT®-Prostate
Transfection Kit (Mirus), and cells untreated or
treated with scrambled siRNA were used as con-
trols. Motility was assessed 72 h post-transfection
as described below. Cell lines stably depleted of
endogenous IGF-IR (T24T) or DDR1 (UMUC-3)
were generated by transfecting the pRS-sh-Scr
(scrambled shRNAs) and pRS/shIGF-IR or
shDDR1 plasmids expressing shRNAs against
human IGF-IR or DDR1 (OriGene Technologies,
Inc.) using the TransIT®-Prostate Transfection Kit
(Mirus). Cells were selected in medium supplement-
ed with 2 μg/ml of Puromycin. After selection, pools
9
of either IGF-IR or DDR1-depleted T24T or UMUC-3
cells respectively were tested for IGF-IR or DDR1
expression levels by immunoblot using specific
polyclonal antibodies as previously described
[69,73,84].
Co-immunoprecipitation and Western immuno-
blots
Serum-starved 5637 and T24T cells were stimu-
lated with 10 nM of either IGF-I (5637), IGF-II or
insulin (T24T), for 5 min, lysed and 2 mg of proteins
immunoprecipitated with either IGF-IR or IR using a
monoclonal antibody against the IGF-IR (Oncogene
Sciences) or IR α-subunits (Novus Biologicals) as
previously described [84,108]. After SDS-PAGE,
membranes were immunoblotted with β-subunit-
specific anti-IGF-IR or anti-IR polyclonal antibodies
(Santa Cruz Biotechnology). DDR1 was immuno-
precipitated using anti-DDR1 polyclonal antibodies
(C-20, sc-532, Santa Cruz Biotechnology) and
detected by immunoblot with anti-DDR1 antibodies
(C-20, sc-532, Santa Cruz Biotechnology) as de-
scribed [73–75]. Phospho-DDR1 (Tyr792), Pyk2,
and myosin IIA antibodies were from Cell Signaling
Technology.
Migration and colony formation assays
Cell motility was assessed in Boyden chambers as
described [80,81,109]. Briefly, HTS FluoroBloks™
inserts (Becton Dickinson) were saturated with PBS-
1% bovine serum albumin for 2 h at room temper-
ature. Serum-starved cells were labeled with DiI
(Molecular Probes) for 20 min at 37 °C and then
seeded in the HTS FluoroBloks™ upper chamber in
either SFM or SFM supplemented with either 1%
FBS, 10 nM of IGF-I, IGF-II or insulin and incubated
at 37 °C for either 4 (1% serum) or 18 h. After fixing in
4% paraformaldehyde, membranes were mounted on
a slide, and migrated cells were counted and photo-
graphed with a Zeiss Axiovert 200M live-cell micro-
scope at the Kimmel Cancer Center Confocal
Microscopy Core Facility. Anchorage-independent
grow was measured by colony formation in soft-agar
as previously described [80,81,110,111]. Briefly, cells
were seeded in soft-agar at a density of 5 × 103 cells/
35 mm plate and counted after three weeks in culture.
Colonies N 150 μm were scored as positive.
Confocal microscopy and immunohistochemistry
Confocal microscopy analysis was performed as
previously described [112]. Serum-starved 5637 and
T24T cells plated on 0.2% gelatin-coated four-well
chamber slides (Nunc, Thermo Fisher Scientific)
were stimulated with either IGF-I or IGF-II (10 nM)
for 10 or 30 min. After treatment, cells were rinsed
twice with cold DPBS (Thermo Fisher Scientific) and
fixed in 4% (wt/vol) paraformaldehyde for 30 min.
After washing, F-actin was detected using Alexa
Fluor® 594-phalloidin followed by confocal analysis.
Images are representative of 10 independent fields
from three independent experiments. Confocal
analysis was performed using a 63×, 1.3 oil-
immersion objective of an LSM-780 confocal laser-
scanning microscope (ZEISS) with filters set at 450/
594 nm for dual-channel imaging. All images were
analyzed using ImageJ (National Institute of Health)
and Adobe Photoshop CS6 (Adobe Systems).
DDR1 expression was analyzed by immunohisto-
chemistry as described [80,81,113] on a Biomax
human bladder cancer tissue microarray (BL208) at
the Translational Core Facility of the Sidney Kimmel
Cancer Center. The antibody used was an anti-DDR1
rabbit monoclonal antibody (Abcam, ab108608) at a
dilution of 1:400. Detailed product specifications of the
bladder tissue array can be found at http://www.
biomax.us/tissue-arrays/Bladder/BL208. The array
contains 43 cases of urothelial carcinoma, 7 adeno-
carcinoma, 6 carcinoma in situ, 4metastatic carcinoma
and 9 bladder tissue, with triplicate cores per case.
Quantification of DDR1 staining in the microarray was
doneutilizing ImageJ (NIH). The threshold of staining of
each image acquired was adjusted in order to show
only the specific staining.
Statistical analysis
Results of multiple experiments are expressed as
mean ± SD. All statistical analyses were carried out
with SigmaStat for Windows v3.10 (Systat Software,
Inc., Port Richmond, CA). Significance of the
differences was evaluated by Student's t-test with
significance at p b 0.05. All data presented herein
were collected from a minimum of three indepen-
dent, biological experiments. Where more than two
experimental conditions were compared, one-way
ANOVA was performed.
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